back to US directory
us clinical guidance

Gout flares and urate-lowering therapy

ACR-based diagnosis, acute flare treatment, allopurinol-first treat-to-target therapy, prophylaxis and comorbidity-aware care.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with suspected or established monosodium-urate crystal arthritis, including acute flare and long-term urate lowering. Septic arthritis, asymptomatic hyperuricemia, tumor lysis, pediatric disease and pregnancy require separate decisions.
sources for this section:ACR Gout

The Bottom Line

  • Confirm uncertain gout with synovial-fluid crystal analysis when feasible, especially for a first, atypical or high-risk hot joint; serum urate can be normal during a flare and does not exclude infection.
  • Treat a flare early with colchicine, an NSAID or glucocorticoid selected from kidney, gastrointestinal, cardiovascular, infection and interaction risk; use low-dose rather than high-dose colchicine.
  • Strongly recommend urate-lowering therapy for tophaceous gout, radiographic damage from gout or frequent flares, and conditionally consider it in the specific first-flare or infrequent-flare situations defined by ACR.
  • Use allopurinol as preferred first-line urate-lowering therapy, including chronic kidney disease, start low and titrate using serial serum urate to a target below 6 mg/dL rather than leaving a fixed low dose.
  • Provide anti-inflammatory prophylaxis for at least three to six months when initiating urate lowering, extending it when flares continue, and educate that early flares do not mean treatment failure.
sources for this section:ACR Gout

Practical clinical workflow

1
Assess joint distribution, onset, fever, skin break, prior crystals, medicines, alcohol, diet, kidney disease and stones; aspirate and culture when septic arthritis is plausible.
2
Choose immediate anti-inflammatory treatment and provide a future flare plan, accounting for renal function, anticoagulation, interactions and previous response.
3
Review indication for urate lowering and modifiable contributors; test HLA-B*5801 before allopurinol in patients of Southeast Asian or African American ancestry as conditionally recommended.
4
Start low-dose allopurinol or an alternative when appropriate, titrate to serum urate below 6 mg/dL and monitor adherence, flares, renal function and toxicity.
5
Address weight, alcohol, high-fructose intake and comorbid hypertension, cardiovascular and kidney disease without implying lifestyle alone replaces urate-lowering therapy when indicated.
sources for this section:ACR Gout

Safety boundaries and escalation

  • A hot joint with fever, bacteremia risk or immunosuppression is septic arthritis until reasonably excluded; crystals and infection can coexist.
  • Allopurinol hypersensitivity with rash, fever, mucosal involvement, facial edema or organ injury is an emergency and the drug must not be casually restarted.
  • Colchicine toxicity risk rises with kidney or liver impairment and CYP3A4 or P-glycoprotein interactions; verify the current FDA label and dosing.
  • NSAIDs and glucocorticoids can worsen bleeding, kidney, heart failure, glucose and infection risk; select flare therapy from the whole patient rather than a default recipe.
sources for this section:ACR Gout

Localization

Use the ACR treat-to-target guideline, US ancestry-specific HLA-B*5801 recommendation and current FDA labels. Insurance coverage affects agent access but should not replace shared clinical decisions.
sources for this section:ACR Gout

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of Rheumatology2020 American College of Rheumatology Guideline for the Management of GoutDOI 10.1002/acr.24180 路 published 2020-05-11 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.